NCT02960815View on ClinicalTrials.gov

Imiquimod and Influenza Vaccine for Immunocompromised Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Influenza Vaccine
Interventions
BIOLOGICAL

Intanza

BIOLOGICAL

Mutagrip

DRUG

Aldara

Trial Locations (1)

1011

CHUV, Lausanne

All Listed Sponsors
lead

University of Lausanne Hospitals

OTHER

NCT02960815 - Imiquimod and Influenza Vaccine for Immunocompromised Patients | Biotech Hunter | Biotech Hunter